CX juxtarenal aortic session brings new stenting data to light

A series of first-to-podium presentations at the 2023 Charing Cross (CX) International Symposium (25–27 April, London, UK) offered new data on balloon-expandable bridging covered stents and self-expanding grafts, as well as the role of covered stents in the treatment in chronic mesenteric ischaemia (CMI). Before that, however, was a presentation on the Advanta V12 balloon-expandable covered stent (Getinge).

IN A REVIEW OF 20 YEARS OF concerning renal arteries, which were 98.2±0.5% at eight years for fenestrations and 77.3±5.9% at eight years for branches.

Concluding, Verhoeven made clear that despite disparities in the data, Advanta V12 has persisted as an invaluable device, which has provided “excellent” handling and flaring over the course of 20-plus years of use. Placing emphasis on the long-term patency rates that have made the Advanta V12 an invaluable tool within F/BEVAR, Verhoeven finally alluded to its steadfast place within the future of treatment.

Bridging covered stents and self-expanding grafts “similar” on primary patency Konstantinos Spanos (University of Thessaly, Larissa, Greece) presented meta-analysis data of comparative studies evaluating the balloon-expandable bridging covered stent versus the selfexpanding stent graft for BEVAR, also in a first-to-podium presentation at CX. The findings showed that balloon-expandable stent grafts and self-expandable stent grafts perform “similarly” when compared via primary patency and branch-related endoleak during mid-term follow-up.

Addressing the audience, Spanos explained that currently available stent grafts— bridging covered stents or self-expanding grafts—are not originally designed as bridging stents for complex aortic repair with branched devices. Continuing, he outlined that the aim of the current review was to evaluate the impact of each type of bridging stent graft on target vessel outcomes during the mid-term followup after BEVAR.

In total, Spanos stated, 96% of target vessels remained patent using bridging covered stents and 97% using selfexpanding grafts, and he added the overall pooled primary patency rate did not differ between groups. Concerning revascularisation, Spanos also asserted that no significant differences were found between the two groups, showing 97% for bridging covered stents and 99% for selfexpanding grafts, respectively.

Of note however, Spanos confirmed that the researchers found a lower risk for target vessel instability using self-expanding stent grafts during revascularisation when compared to bridging covered stents, which he defined as any death or rupture related to a side branch complication.

Concluding his presentation, Spanos conveyed that although the performance of bridging covered stents versus self-expanding stent grafts was similar, current data from retrospective